The company said it is evaluating its strategic options regarding ADX-097 as it shifts efforts over to pushing bempikibart.

WALTHAM, Mass. - Q32 Bio Inc. (NASDAQ: QTTB), a clinical-stage biotechnology firm trading at $3.18 with a market cap of $38.55 million, announced a strategic shift to prioritize the development of its ...

If you haven’t found the right treatment for your alopecia areata yet, it may be right around the corner. There’s no cure for alopecia areata, but even with this condition, your hair follicles ...

For some people with alopecia areata, it does. It’s hard to predict. If your hair loss is mild, or less than 50%, you’re more likely to find an effective treatment that stops your immune ...

Panelists discuss how switching therapies in patients with alopecia areata (AA) is often necessary when initial treatments ...

Panelists discuss how the data from the BRAVE-AA1 and BRAVE-AA2 phase 3 trials demonstrated the safety and efficacy of baricitinib, leading to its FDA approval in 2022 as the first systemic treatment ...

A phase 3 study demonstrated that ritlecitinib was effective and well tolerated in patients with alopecia areata and ≥ 25% ...

Q32 Bio Inc. (Nasdaq: QTTB) ("Q32 Bio"), a clinical stage biotechnology company focused on developing biologic therapeutics to restore immune homeostasis, today announced a corporate restructuring to ...

Stress can lead to noticeable hair loss, usually months after a stressful situation occurs. This type of hair loss is ...

The risk for alopecia areata is increased among patients with lower serum levels of vitamin D and zinc, but no relationship was observed with copper.

Q32 Bio (Nasdaq: QTTB) has announced a corporate restructuring, shifting its focus entirely to the development of its lead ...

Q32 Bio (QTTB) announced a corporate restructuring to focus on the advancement of its bempikibart clinical development program for the ...